- Home
- CRVO vs ADVM Comparison
CRVO vs ADVM Comparison
Compare CRVO & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- ADVM
- Stock Information
- Founded
- CRVO 2001
- ADVM 2006
- Country
- CRVO United States
- ADVM United States
- Employees
- CRVO N/A
- ADVM N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRVO Health Care
- ADVM Health Care
- Exchange
- CRVO Nasdaq
- ADVM Nasdaq
- Market Cap
- CRVO 95.4M
- ADVM 98.0M
- IPO Year
- CRVO N/A
- ADVM 2014
- Fundamental
- Price
- CRVO $9.80
- ADVM $2.93
- Analyst Decision
- CRVO Strong Buy
- ADVM Strong Buy
- Analyst Count
- CRVO 8
- ADVM 6
- Target Price
- CRVO $25.43
- ADVM $25.83
- AVG Volume (30 Days)
- CRVO 1.5M
- ADVM 176.5K
- Earning Date
- CRVO 05-13-2025
- ADVM 04-15-2025
- Dividend Yield
- CRVO N/A
- ADVM N/A
- EPS Growth
- CRVO N/A
- ADVM N/A
- EPS
- CRVO N/A
- ADVM N/A
- Revenue
- CRVO $9,737,974.00
- ADVM $1,000,000.00
- Revenue This Year
- CRVO N/A
- ADVM $1,187.80
- Revenue Next Year
- CRVO N/A
- ADVM N/A
- P/E Ratio
- CRVO N/A
- ADVM N/A
- Revenue Growth
- CRVO 36.29
- ADVM N/A
- 52 Week Low
- CRVO $1.80
- ADVM $2.89
- 52 Week High
- CRVO $25.69
- ADVM $11.87
- Technical
- Relative Strength Index (RSI)
- CRVO 55.40
- ADVM 31.79
- Support Level
- CRVO $9.03
- ADVM $3.07
- Resistance Level
- CRVO $10.89
- ADVM $3.71
- Average True Range (ATR)
- CRVO 1.90
- ADVM 0.46
- MACD
- CRVO -0.29
- ADVM -0.12
- Stochastic Oscillator
- CRVO 32.37
- ADVM 9.20
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.